265 related articles for article (PubMed ID: 15553663)
1. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
Yamagishi S; Takeuchi M
Drugs Exp Clin Res; 2004; 30(4):169-75. PubMed ID: 15553663
[TBL] [Abstract][Full Text] [Related]
2. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
Yamagishi S; Matsui T; Nakamura K; Takeuchi M
Int J Tissue React; 2005; 27(4):189-95. PubMed ID: 16440584
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells.
Zhang FL; Gao HQ; Shen L
J Cardiovasc Pharmacol; 2007 Oct; 50(4):434-40. PubMed ID: 18049312
[TBL] [Abstract][Full Text] [Related]
4. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation.
Yamagishi S; Inagaki Y; Kikuchi S
Drugs Exp Clin Res; 2003; 29(4):147-52. PubMed ID: 15018305
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Okuda S; Imaizumi T
Ophthalmic Res; 2008; 40(1):10-5. PubMed ID: 18025836
[TBL] [Abstract][Full Text] [Related]
6. Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression.
Yamagishi S; Takeuchi M
Drugs Exp Clin Res; 2004; 30(4):163-8. PubMed ID: 15553662
[TBL] [Abstract][Full Text] [Related]
7. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
[TBL] [Abstract][Full Text] [Related]
8. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2009 Jul; 385(2):269-72. PubMed ID: 19460355
[TBL] [Abstract][Full Text] [Related]
9. Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells.
Yamagishi S; Takeuchi M
Drugs Exp Clin Res; 2005; 31(1):13-7. PubMed ID: 15921025
[TBL] [Abstract][Full Text] [Related]
10. Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells.
Yamagishi S; Kikuchi S; Takenaka K; Takeuchi M
Drugs Exp Clin Res; 2005; 31(5-6):221-6. PubMed ID: 16425979
[TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced glycation end products in endothelial cells.
Zhang FL; Gao HQ; Wu JM; Ma YB; You BA; Li BY; Xuan JH
J Cardiovasc Pharmacol; 2006 Aug; 48(2):47-53. PubMed ID: 16954821
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells.
Chen J; Huang L; Song M; Yu S; Gao P; Jing J
J Cardiovasc Pharmacol; 2009 May; 53(5):359-67. PubMed ID: 19276989
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2012 Nov; 44(12):891-5. PubMed ID: 22864903
[TBL] [Abstract][Full Text] [Related]
15. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
Chello M; Spadaccio C; Lusini M; Covino E; Blarzino C; De Marco F; Di Domenico F; Coccia R
Diabetes Metab Res Rev; 2009 Jul; 25(5):420-6. PubMed ID: 19405075
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2011 Sep; 43(10):731-4. PubMed ID: 21932180
[TBL] [Abstract][Full Text] [Related]
19. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF.
Yamagishi S; Nakamura K; Ueda S; Kato S; Imaizumi T
Cell Tissue Res; 2005 Jun; 320(3):437-45. PubMed ID: 15846509
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.
Ide Y; Matsui T; Ishibashi Y; Takeuchi M; Yamagishi S
Microvasc Res; 2010 Sep; 80(2):227-32. PubMed ID: 20381502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
